Literature DB >> 24801380

Doxorubicin and 5-fluorouracil induced accumulation and transcriptional activity of p53 are independent of the phosphorylation at serine 15 in MCF-7 breast cancer cells.

Matthew T Balmer1, Ryan D Katz1, Si Liao1, James S Goodwine1, Susannah Gal1.   

Abstract

The chemotherapeutic agents doxorubicin (dox) or 5-fluorouracil (5FU) are used to treat cancer cells as they cause irreparable DNA damage, inducing these aberrant cells to undergo cell death. The mediator of this process is presumed to be in part the tumor suppressor p53 which regulates genes involved in DNA repair and cell death. When MCF-7 breast cancer cells are treated with these drugs, we observed that the level of p53 and the p53 negative regulator, Mdm2, increased, as seen by others. But contrary to some reports, we observed minimal phosphorylation of p53 at serine 15 in MCF-7 cells after drug treatment. Interestingly, we determined that there was differential regulation of the kinases ATM and Chk2 with the drug treatments, likely the cause for the lack of phosphorylation of p53. We found a dramatic drop in p53 DNA binding affinity for p21 and other gene response elements (RE) after drug treatment. To determine if the p53 that accumulated in the drug treated cells was functionally active, we monitored changes in the protein products of two p53-regulated genes following drug treatment with and without the addition of a p53-specific siRNA. In response to 5FU, both p21 and Mdm2 proteins increased and that increase was alleviated if a p53-specific siRNA was added. This effect was not seen with the addition of dox. Thus, the phosphorylation at serine 15 is not necessary for the functional activation of this transcription factor. We propose a new model for the regulation of p53, Mdm2, and MdmX after drug treatment.

Entities:  

Keywords:  5-fluorouracil; ATM; Chk2; DNA binding; MCF-7; Mdm2; MdmX; doxorubicin; p53; posttranslational modification

Mesh:

Substances:

Year:  2014        PMID: 24801380      PMCID: PMC4119068          DOI: 10.4161/cbt.29112

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  57 in total

1.  Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein.

Authors:  D A Sharp; S A Kratowicz; M J Sank; D L George
Journal:  J Biol Chem       Date:  1999-12-31       Impact factor: 5.157

2.  Mutual dependence of MDM2 and MDMX in their functional inactivation of p53.

Authors:  Jijie Gu; Hidehiko Kawai; Linghu Nie; Hiroyuki Kitao; Dmitri Wiederschain; Aart G Jochemsen; John Parant; Guillermina Lozano; Zhi-Min Yuan
Journal:  J Biol Chem       Date:  2002-04-12       Impact factor: 5.157

3.  A small-molecule inhibitor of MDMX activates p53 and induces apoptosis.

Authors:  Hongbo Wang; Xujun Ma; Shumei Ren; John K Buolamwini; Chunhong Yan
Journal:  Mol Cancer Ther       Date:  2010-11-12       Impact factor: 6.261

4.  MDMX: a novel p53-binding protein with some functional properties of MDM2.

Authors:  A Shvarts; W T Steegenga; N Riteco; T van Laar; P Dekker; M Bazuine; R C van Ham; W van der Houven van Oordt; G Hateboer; A J van der Eb; A G Jochemsen
Journal:  EMBO J       Date:  1996-10-01       Impact factor: 11.598

5.  5-fluorouracil activation of p53 involves an MDM2-ribosomal protein interaction.

Authors:  Xiao-Xin Sun; Mu-Shui Dai; Hua Lu
Journal:  J Biol Chem       Date:  2007-01-22       Impact factor: 5.157

6.  The DNA binding and accumulation of p53 from breast cancer cell lines and the link with serine 15 phosphorylation.

Authors:  Debolina Ray; Keith R Murphy; Susannah Gal
Journal:  Cancer Biol Ther       Date:  2012-08-01       Impact factor: 4.742

7.  Phosphorylation site interdependence of human p53 post-translational modifications in response to stress.

Authors:  Shin'ichi Saito; Hiroshi Yamaguchi; Yuichiro Higashimoto; Connie Chao; Yang Xu; Albert J Fornace; Ettore Appella; Carl W Anderson
Journal:  J Biol Chem       Date:  2003-07-14       Impact factor: 5.157

8.  Regulation of p53 stability and function in HCT116 colon cancer cells.

Authors:  Matthias D Kaeser; Stephanie Pebernard; Richard D Iggo
Journal:  J Biol Chem       Date:  2003-12-09       Impact factor: 5.157

9.  Phosphorylation of p53 on Thr55 by ERK2 is necessary for doxorubicin-induced p53 activation and cell death.

Authors:  Pei Yen Yeh; Shuang-En Chuang; Kun-Huei Yeh; Ying Chyi Song; Lucia Ling-Yuan Chang; Ann-Lii Cheng
Journal:  Oncogene       Date:  2004-04-29       Impact factor: 9.867

10.  FOXO3 signalling links ATM to the p53 apoptotic pathway following DNA damage.

Authors:  Young Min Chung; See-Hyoung Park; Wen-Bin Tsai; Shih-Ya Wang; Masa-Aki Ikeda; Jonathan S Berek; David J Chen; Mickey C-T Hu
Journal:  Nat Commun       Date:  2012       Impact factor: 14.919

View more
  7 in total

1.  Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties.

Authors:  James A McCubrey; Akshaya K Meher; Shaw M Akula; Stephen L Abrams; Linda S Steelman; Michelle M LaHair; Richard A Franklin; Alberto M Martelli; Stefano Ratti; Lucio Cocco; Fulvio Barbaro; Przemysław Duda; Agnieszka Gizak
Journal:  Aging (Albany NY)       Date:  2022-04-27       Impact factor: 5.682

2.  Doxorubicin attenuates CHIP-guarded HSF1 nuclear translocation and protein stability to trigger IGF-IIR-dependent cardiomyocyte death.

Authors:  Chih-Yang Huang; Wei-Wen Kuo; Jeng-Fan Lo; Tsung-Jung Ho; Pei-Ying Pai; Shu-Fen Chiang; Pei-Yu Chen; Fu-Jen Tsai; Chang-Hai Tsai; Chih-Yang Huang
Journal:  Cell Death Dis       Date:  2016-11-03       Impact factor: 8.469

3.  Annexin/S100A Protein Family Regulation through p14ARF-p53 Activation: A Role in Cell Survival and Predicting Treatment Outcomes in Breast Cancer.

Authors:  Diana Hatoum; Daniel Yagoub; Alireza Ahadi; Najah T Nassif; Eileen M McGowan
Journal:  PLoS One       Date:  2017-01-09       Impact factor: 3.240

4.  Anacardic acid inhibits pancreatic cancer cell growth, and potentiates chemotherapeutic effect by Chmp1A - ATM - p53 signaling pathway.

Authors:  Maiyon Park; Danielle Upton; Melodie Blackmon; Valerie Dixon; Scott Craver; Dawn Neal; Derek Perkins
Journal:  BMC Complement Altern Med       Date:  2018-02-20       Impact factor: 3.659

5.  Effect of the p53-tristetraprolin-stathmin-1 pathway on trophoblasts at maternal-fetal interface.

Authors:  Xiao-Ling Ma; Xiao-Cui Li; Fu-Ju Tian; Si-Ming Zhang; Xiao-Rui Liu; Yan Zhang; Jian-Xia Fan; Yi Lin
Journal:  PLoS One       Date:  2017-06-28       Impact factor: 3.240

6.  p53 inhibits the expression of p125 and the methylation of POLD1 gene promoter by downregulating the Sp1-induced DNMT1 activities in breast cancer.

Authors:  Liang Zhang; Weiping Yang; Xiao Zhu; Changyuan Wei
Journal:  Onco Targets Ther       Date:  2016-03-10       Impact factor: 4.147

Review 7.  The Roles of p53 in Mitochondrial Dynamics and Cancer Metabolism: The Pendulum between Survival and Death in Breast Cancer?

Authors:  David E Moulder; Diana Hatoum; Enoch Tay; Yiguang Lin; Eileen M McGowan
Journal:  Cancers (Basel)       Date:  2018-06-08       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.